Plant Summary
Plant Information
TCMBank_ID: | TCMBANKHE007523 |
ID: | TCMBANKHE007523 |
植物拉丁名: |
|
功能与主治: | To remove toxic heat, and to cause subsidence of eruptions by reducing heat in blood./Treatment of fever and eruptions in epidemic diseases, cough and asthma due to heat in the lung, inflammation of the throat, mnmps, erysipelas, carbuncle. |
药用植物名: | 蓼大青叶 |
治疗类型: | 清热解毒药 |
TCM_ID_id: | 3416 |
SymMap_id: | 247 |
TCMSP_id: | 995 |
植物对应的化合物
| 化合物ID | 化合物名 | 别名 | 分子式 | 分子质量 | Smiles |
|---|
| TCMBANKIN000080 | Deoxycholic Acid | SCHEMBL11962424; deoxycholic acid; Deoxycholicacid; deoxycholicacid; AKOS015965182; AC-20221 | C24H40O4 | 392.57 | CC(CCC(=O)O)C1CCC2C1(C(CC3C2CCC4C3(CCC(C4)O)C)O)C |
| TCMBANKIN000094 | choline | Choline chloride; choline hydroxide | C5H14NO+ | 104.17 g/mol | C[N+](C)(C)CCO |
| TCMBANKIN000930 | Glucocheirolin_qt | 276.37 | |||
| TCMBANKIN001443 | lithospermate b | ANUBYMNVOPVATP-OAZHBLANSA-L; 122021-74-3; MolPort-039-339-215; Monomethyl lithospermate B; AC1O5P3G; magnesium 3-(3,4-dihydroxyphenyl)-2-[(E)-3-[2-(3,4-dihydroxyphenyl)-3-[3-(3,4-dihydroxyphenyl)-1-oxido-1-oxopropan-2-yl]oxycarbonyl-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyl]oxypropanoate | C36H28MgO16 | 740.9 g/mol | C1=CC(=C(C=C1CC(C(=O)[O-])OC(=O)C=CC2=C3C(C(OC3=C(C=C2)O)C4=CC(=C(C=C4)O)O)C(=O)OC(CC5=CC(=C(C=C5)O)O)C(=O)[O-])O)O.[Mg+2] |
| TCMBANKIN001715 | Thladioside H1_qt | 470.76 | |||
| TCMBANKIN003340 | TR-saponin A_qt | C51H76O20 | 1009.14 | ||
| TCMBANKIN005866 | tyr-gly | AC1O530H; ZINC1569734; SCHEMBL6047681; 2-[[(2R)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetic acid; BIT3162 | C11H14N2O4 | 238.24 g/mol | C1=CC(=CC=C1CC(C(=O)NCC(=O)O)N)O |
| TCMBANKIN008152 | Glucobrassicin-1-Sulfonate | glucobrassicin-1-sulfonate | C16H20N2O12S3 | 528.5 g/mol | C1=CC=C2C(=C1)C(=CN2S(=O)(=O)O)CC(=NOS(=O)(=O)O)SC3C(C(C(C(O3)CO)O)O)O |
| TCMBANKIN008751 | Cherianoine | 7-hydroxy-6,8-dimethoxy-2-methyl-isoquinolin-1-one; 7-hydroxy-6,8-dimethoxy-2-methyl-isocarbostyril; 7-hydroxy-6,8-dimethoxy-2-methylisoquinolin-1-one; cherianoine; 7-hydroxy-6,8-dimethoxy-2-methyl-1-isoquinolinone; AC1NSTIB | C12H13NO4 | 235.24 g/mol | CN1C=CC2=CC(=C(C(=C2C1=O)OC)O)OC |
| TCMBANKIN012117 | beta-ala-cys-his-ileu-phe | ||||
| TCMBANKIN012169 | Glucobrassicin-1-Sulfonate_qt | 1-sulpho-3-indolylmethyl-glucosinolate_qt | 365.42 | ||
| TCMBANKIN012217 | deoxycorticosterone | AC1NSUE3; I14-53273; SCHEMBL15763287; (10R,13S,17S)-17-(2-hydroxyacetyl)-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one; AKOS015915651 | C21H30O3 | 330.5 g/mol | CC12CCC3C(C1CCC2C(=O)CO)CCC4=CC(=O)CCC34C |
| TCMBANKIN014088 | TR-saponin A | tr-saponin a | C51H76O20 | 1009.14 | CC=C(C)C(=O)OC1C(C2(C(CC1(C)C)C3=CCC4C5(CCC(C(C5CCC4(C3(C(C2O)O)C)C)(C)C(=O)OC)OC6C(C(C(C(O6)C(=O)O)O)OC7C(C(C(CO7)O)O)O)O)C)CO)OC(=O)C(=CC)C |
| TCMBANKIN015051 | isatisine,a | 406.42 | |||
| TCMBANKIN016561 | 9alpha,13alpha-dihydroxylisopropylidenylisatisine,a | 446.49 | |||
| TCMBANKIN018558 | ho-glu-gly-gly-glu-gly-asp-gly | ||||
| TCMBANKIN020346 | indican_qt | C14H17NO6 | 295.29 | ||
| TCMBANKIN022214 | Indicaxanthin | indicaxanthin; (2S)-1-[(2E)-2-[(2S)-2,6-dicarboxy-2,3-dihydro-1H-pyridin-4-ylidene]ethylidene]pyrrolidin-1-ium-2-carboxylate; 2181-75-1; SCHEMBL288232; AC1O1I0D; C08549; CHEBI:5896; (1Z,2S)-1-{(2E)-2-[(2S)-2,6-Dicarboxy-2,3-dihydro-4(1H)-pyridinylidene]ethylidene}-2-pyrrolidinium carboxylate (Indicaxanthin) | C14H16N2O6 | 308.29 | C1CC([N+](=CC=C2CC(NC(=C2)C(=O)O)C(=O)O)C1)C(=O)[O-] |
| TCMBANKIN024103 | gly-cys-cys-gly | ||||
| TCMBANKIN025358 | benzoic acid | Benzoic acid, 2-[(carboxymethyl)amino]-4-chloro-; 2-[(carboxymethyl)amino]-4-chlorobenzoic acid; DTXSID70455462; BG00311790; AC-17987; AX8062950; 2-carboxymethylamino-4-chlorobenzoic acid; KB-223858; AK140629; 99282-79-8; benzoicacid; CTK5I0315; 2-(Carboxymethyl-amino)-4-chloro-; AKOS015963713; SCHEMBL3236365; 2-(carboxymethylamino)-4-chlorobenzoic acid; benzoic acid ; 2-(CARBOXYMETHYL-AMINO)-4-CHLORO-BENZOIC ACID; AJ-79604; 2-((Carboxymethyl)amino)-4-chlorobenzoic acid; UDXGKLGUAJLLCJ-UHFFFAOYSA-N; ZINC21988796 | C7H6O2 | 122.12 | C1=CC(=C(C=C1Cl)NCC(=O)O)C(=O)O |
| TCMBANKIN026747 | 7,9-dihydroxy-6-(4-hydroxyphenyl)pyrano[2,3-f][1,3]benzodioxol-8-one | 7,9-dihydroxy-6-(4-hydroxyphenyl)-8-pyrano[2,3-f][1,3]benzodioxolone | C16H10O7 | 314.25 | |
| TCMBANKIN026796 | saponarin_qt | C27H30O15 | 594.52 | ||
| TCMBANKIN027083 | Isatidine | isatidine | C18H25NO6 | 351.39 | CC=C1CC(C(C(=O)OCC2=CC[N+]3(C2C(CC3)OC1=O)[O-])(CO)O)C |
| TCMBANKIN027153 | bilirubin | 3-[5-[(4-ethenyl-3-methyl-5-oxidanylidene-pyrrol-2-ylidene)methyl]-2-[[5-[(3-ethenyl-4-methyl-5-oxidanylidene-pyrrol-2-ylidene)methyl]-3-(3-hydroxy-3-oxopropyl)-4-methyl-3H-pyrrol-2-yl]methyl]-4-methyl-3H-pyrrol-3-yl]propanoic acid; A834413; 3-[2-[[3-(2-carboxyethyl)-5-[(3-ethenyl-4-methyl-5-oxo-2-pyrrolylidene)methyl]-4-methyl-3H-pyrrol-2-yl]methyl]-5-[(4-ethenyl-3-methyl-5-oxo-2-pyrrolylidene)methyl]-4-methyl-3H-pyrrol-3-yl]propanoic acid | C33H36N4O6 | 584.7 g/mol | CC1=C(NC(=C1CCC(=O)O)CC2=C(C(=C(N2)C=C3C(=C(C(=O)N3)C)C=C)C)CCC(=O)O)C=C4C(=C(C(=O)N4)C=C)C |
| TCMBANKIN028407 | Neoglucobrassicin_qt | C17H22N2O10S2 | 478.49 | ||
| TCMBANKIN029548 | [(3S,4R,5R)-5-[[(2R,3S,4S,5R,6S)-6-(2-acetyl-5-methoxyphenoxy)-3,4,5-trihydroxyoxan-2-yl]methoxy]-3,4-dihydroxyoxolan-3-yl]methyl 3,4,5-trihydroxybenzoate | [(3S,4R,5R)-5-[[(2R,3S,4S,5R,6S)-6-(2-ethanoyl-5-methoxy-phenoxy)-3,4,5-trihydroxy-oxan-2-yl]methoxy]-3,4-dihydroxy-oxolan-3-yl]methyl 3,4,5-trihydroxybenzoate; [(3S,4R,5R)-5-[[(2R,3S,4S,5R,6S)-6-(2-acetyl-5-methoxy-phenoxy)-3,4,5-trihydroxy-tetrahydropyran-2-yl]methoxy]-3,4-dihydroxy-tetrahydrofuran-3-yl]methyl 3,4,5-trihydroxybenzoate; 3,4,5-trihydroxybenzoic acid [(3S,4R,5R)-5-[[(2R,3S,4S,5R,6S)-6-(2-acetyl-5-methoxyphenoxy)-3,4,5-trihydroxy-2-tetrahydropyranyl]methoxy]-3,4-dihydroxy-3-tetrahydrofuranyl]methyl ester; 3,4,5-trihydroxybenzoic acid [(3S,4R,5R)-5-[[(2R,3S,4S,5R,6S)-6-(2-acetyl-5-methoxy-phenoxy)-3,4,5-trihydroxy-tetrahydropyran-2-yl]methoxy]-3,4-dihydroxy-tetrahydrofuran-3-yl]methyl ester | C27H32O16 | 612.53 | |
| TCMBANKIN029746 | indoxyl | 151864-03-8; 1H-INDOLOL; 480-93-3; CHEBI:17840; benzoyl benzenecarboperoxoate; (2S,4R)-N-[2-chloro-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide; 1H-Indol-3-ol; C05658; Indoxyl; 69594-78-1; AC1MJ6M8; ZINC00152333 | C8H7NO | 133.15 g/mol | C1=CC=C2C(=C1)C(=CN2)O |
| TCMBANKIN032096 | triterpenoidsaponin | triterpenoid saponin | 767.07 | CC1C2C(C(C(O1)OC3C(C(COC3OC(=O)C45CCC(CC4(C6=CCC7(C(C6(CC5)C)(CCC8C7(CC(C(C8(C)CO)OC9C(C(C(C(O9)CO)O)O)OC1C(C(C(C(O1)C(=O)CC(CC(=O)O2)(C)O)O)O)O)O)C)C)C)C)(C)C)O)O)O)OC1C(C(C(CO1)O)O)O | |
| TCMBANKIN032162 | ergotamine | C33H35N5O5 | 581.7 g/mol | CC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CN(C6CC7=CNC8=CC=CC(=C78)C6=C5)C | |
| TCMBANKIN034179 | Thladioside H1 | thladiosideh1; thladioside h1 | 1351.61 | CC1C(C(C(C(O1)OC2C(C(COC2OC(=O)C34CCC(CC3C5=CCC6C7(CCC(C(C7CCC6(C5(CC4)C)C)(C)C=O)OC8C(C(C(C(O8)C(=O)O)O)O)OC9C(C(C(C(O9)CO)O)O)O)C)(C)C)O)O)O)O)OC1C(C(C(CO1)O)OC1C(C(C(CO1)O)O)O)O | |
| TCMBANKIN035399 | glucobrassicin_qt | Glucobrassicin_qt | C16H20N2O9S2 | 448.47 | |
| TCMBANKIN036312 | 20-Hexadecanoylingenol | 20-hexadecanoylingenol | C36H58O6 | 586.94 | CCCCCCCCCCCCCCCC(=O)OCC1=CC2C3C(C3(C)C)CC(C4(C2=O)C=C(C(C4(C1O)O)O)C)C |
| TCMBANKIN036851 | chenodeoxycholic acid | (3alpha,5beta,7alpha,8xi)-3,7-dihydroxycholan-24-oic acid; 3-alpha,7-alpha-Dihydroxycholanic acid; Anthropodesoxycholic acid; SMP1_000064; 7-alpha-Hydroxylithocholic acid; BSPBio_000190; Spectrum5_002009; JN3; CDCA; Acide chenodeoxycholique [INN-French]; Acidum chenodeoxycholicum [INN-Latin]; (4R)-4-[(3R,5S,7R,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid; 3-alpha,7-alpha-Dihydroxycholansaeure [German]; Cholan-24-oic acid, 3,7-dihydroxy-, (3-alpha,5-beta,7-alpha)- (9CI); (4R)-4-[(3R,5S,7R,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]valeric acid; Chenodesoxycholsaeure [German]; 5.BETA.-CHOLANIC ACID-3.ALPHA., SODIUM SALT; AIDS-045143; CCRIS 2195; Gallodesoxycholic acid; AIDS045143; Chenodiol (USAN); Chenix (TN); Chenix; 7alpha-hydroxylithocholic acid; SODIUM URSO; Prestwick1_000285; Chenic acid; 5-beta-Cholan-24-oic acid, 3-alpha,7-alpha-dihydroxy-; HSCI1_000210; D00163; chenodeoxycholicacid; Cholan-24-oic acid, 3,7-dihydroxy-, (3-.alpha., 5-.beta., 7-.alpha.)-; Chenodiol [USAN]; Anthropododesoxycholic acid; SPBio_002409; Prestwick0_000285; Anthropodeoxycholic acid; Cholan-24-oic acid, 3,7-dihydroxy-, (3alpha,5beta,7alpha)-; Chenodeoxycholic acid (JP15/INN); Chenodiol; NSC681066; CHEBI:16755; 474-25-9; Chenodeoxycholic acid; NSC-681066; 3-alpha,7-alpha-Dihydroxy-5-beta-cholan-24-oic acid; SBB002935; BPBio1_000210; 3alpha,7alpha-Dihydroxy-5beta-cholan-24-oic acid; Prestwick2_000285; Acido chenodeoxicholico [INN-Spanish]; LMST04010032; Chendol; C02528; EINECS 207-481-8; Prestwick3_000285; NSC 657949 | C24H40O4 | 392.57 | CC(CCC(=O)O)C1CCC2C1(CCC3C2C(CC4C3(CCC(C4)O)C)O)C |
| TCMBANKIN036857 | biliverdin | biliverdin(2-); biliverdin dianion; CHEBI:57991 | C33H32N4O6-2 | 580.6 g/mol | CC1=C(C(=CC2=C(C(=C(N2)C=C3C(=C(C(=O)N3)C)C=C)C)CCC(=O)[O-])NC1=CC4=NC(=O)C(=C4C)C=C)CCC(=O)[O-] |
| TCMBANKIN036904 | isovitexin | beta-D-isovitexin; LMPK12110338; Iso Vitexin; CHEBI:18330; 61383-34-4; C01714; 61838-34-4; 29702-25-8; 6-beta-D-Glucopyranosyl-4',5,7-trihydroxyflavone; 4H-1-Benzopyran-4-one, 6-beta-D-glucopyranosyl-5,7- dihydroxy-2-(4-hydroxyphenyl)-; 5,7-dihydroxy-2-(4-hydroxyphenyl)-6-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-2-tetrahydropyranyl]-4-chromenone; 6-Glucosylapigenin; Isovitexin; Apigenin-6-C-glucoside; 5,7-dihydroxy-2-(4-hydroxyphenyl)-6-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-methylol-tetrahydropyran-2-yl]chromone; Apigenin 6-C-glucoside; 38953-85-4; NCGC00163578-01; 5,7-dihydroxy-2-(4-hydroxyphenyl)-6-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]chromen-4-one; Saponaretin; 4H-1-Benzopyran-4-one, 6-beta-D-glucopyranosyl-5,7-dihydroxy-2-(4-hydroxyphenyl)- (VAN); AIDS339232; (1S)-1,5-anhydro-1-[5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-6-yl]-D-glucitol; 5,7-dihydroxy-2-(4-hydroxyphenyl)-6-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]chromen-4-one; 6-C-Glucosylapigenin; AIDS-339232 | C20H18O10 | 418.351 | c1(C2=C([H])C(=O)c(c(O[H])c([C@@]3([H])[C@]([H])(O[H])[C@@]([H])(O[H])[C@]([H])(O[H])[C@@]([H])(O[H])O3)c(O[H])c4[H])c4O2)c([H])c([H])c(O[H])c([H])c1[H] |
| TCMBANKIN038777 | isatan B | Isatan B; Isatan B, 6; isatan B; BDBM86106; SCHEMBL19129829; 3,5-dihydroxy-2-(hydroxymethyl)-6-(1H-indol-3-yloxy)tetrahydropyran-4-one | C14H15NO7 | 309.271 | c1([H])c([H])c(c(OC(=O)[C@]([H])(O[C@](C([H])([H])O[H])(O[H])[C@]2([H])O[H])[C@]2([H])O[H])c([H])n3[H])c3c([H])c1[H] |
| TCMBANKIN038964 | isoscoparin | 20013-23-4; Chrysoeriol 6-C-glucoside; 5,7-dihydroxy-2-(4-hydroxy-3-methoxy-phenyl)-6-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]chromen-4-one; (1S)-1,5-anhydro-1-[5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-4-oxo-4H-chromen-6-yl]-D-glucitol; C-Glucosyl-6 chrysoeriol; 5,7-dihydroxy-2-(4-hydroxy-3-methoxy-phenyl)-6-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]chromen-4-one; 5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-6-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-2-tetrahydropyranyl]-4-chromenone; 5,7-dihydroxy-2-(4-hydroxy-3-methoxy-phenyl)-6-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-methylol-tetrahydropyran-2-yl]chromone; 5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-6-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]chromen-4-one; C05990; LMPK12110738; CHEBI:18200; isoscoparin; Isoscoparine | C22H22O11 | 462.403 | c1([C@@]2([H])[C@]([H])(O[H])[C@@]([H])(O[H])[C@]([H])(O[H])[C@@]([H])(C([H])([H])O[H])O2)c(O[H])c([H])c(OC(c3c([H])c(OC([H])([H])[H])c(O[H])c([H])c3[H])=C([H])C4=O)c4c1O[H] |
| TCMBANKIN041189 | saponarin | BDBM50250468; 20310-89-8; 5-hydroxy-2-(4-hydroxyphenyl)-6-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-7-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-chromen-4-one; 5-hydroxy-2-(4-hydroxyphenyl)-6-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-2-tetrahydropyranyl]-7-[[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-2-tetrahydropyranyl]oxy]-4-chromenone; Isovitexin-7-O-beta-D-glucopyranoside; 4H-1-Benzopyran-4-one, 3-((6-O-(6-deoxy-beta-L-mannofuranosyl)-beta-O-galactofuranosyl)oxy)-7-((6-deoxy-beta-L-mannopyranosyl)oxy)-5-hydroxy-2-(4-hydroxyphenyl)-; CHEMBL504279; C08064; Saponarin; 5-hydroxy-2-(4-hydroxyphenyl)-6-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-methylol-tetrahydropyran-2-yl]-7-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-methylol-tetrahydropyran-2-yl]oxy-chromone; 5-hydroxy-2-(4-hydroxyphenyl)-6-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-7-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one; 5-hydroxy-2-(4-hydroxyphenyl)-6-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]-7-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-chromen-4-one | C27H30O15 | 595 | c1([C@@]2([H])[C@]([H])(O[H])[C@@]([H])(O[H])[C@]([H])(O[H])[C@@]([H])(C([H])([H])O[H])O2)c(O[C@]([H])(O[C@]3([H])C([H])([H])O[H])[C@]([H])(O[H])[C@@]([H])(O[H])[C@]3([H])O[H])c([H])c(OC(c4c([H])c([H] )c(O[H])c([H])c4[H])=C([H])C5=O)c5c1O[H] |
| TCMBANKIN041683 | bisindigotin | C32H18N4O2 | 490.511 | c1([H])c([H])c(C(=O)C(c2n([H])c(c([H])c([H])c([H])c3[H])c3c2C(\C(=C(\C(=O)c(c([H])c([H])c([H])c4[H])c45)/N5[H])\N=C6C([H])=C7[H])=C6C([H])=C7[H])=N8)c8c([H])c1[H] | |
| TCMBANKIN043057 | nodakenin | AIDS071124; 2-[2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl]-2,3-dihydrofuro[3,2-g]chromen-7-one; SMR000232306; Nodakenetin, beta-D-glucopyranoside; (+)-Marmesinin; AIDS-071124; MEGxp0_001251; (2R)-2-[1-methyl-1-[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-2-tetrahydropyranyl]oxy]ethyl]-2,3-dihydrofuro[3,2-g]chromen-7-one; 495-31-8; MLS000563463; 7H-Furo[3,2-g][1]benzopyran-7-one, 2-[1-(.beta.-D-glucopyranosyloxy)-1- methylethyl]-2,3-dihydro-, (2R); C09279; Nodakenetin, b-D-glucopyranoside; (2R)-2-[1-methyl-1-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-ethyl]-2,3-dihydrofuro[3,2-g]chromen-7-one; (2R)-2-[2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl]-2,3-dihydrofuro[3,2-g]chromen-7-one; (2R)-2-[1-methyl-1-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-methylol-tetrahydropyran-2-yl]oxy-ethyl]-2,3-dihydrofuro[3,2-g]chromen-7-one; 7H-Furo(3,2-g)(1)benzopyran-7-one, 2-(1-(beta-D-glucopyranosyloxy)-1-methylethyl)-2,3-dihydro-, (2R)-; Nodakenin; AC1NSXVE | C20H24O9 | 408.4 | CC(C)(C1CC2=C(O1)C=C3C(=C2)C=CC(=O)O3)OC4C(C(C(C(O4)CO)O)O)O |
| TCMBANKIN045816 | decursidin | C24H26O7 | 426.5 g/mol | CC(=CC(=O)OC1C(C(OC2=C1C=C3C=CC(=O)OC3=C2)(C)C)OC(=O)C=C(C)C)C | |
| TCMBANKIN046408 | isoorientin | isoorientin 7-olate; isoorientin(1-); Isoorientin; AIDS-026707; 2-(3,4-Dihydroxyphenyl)-6-beta-D-glucopyranosyl-5,7-dihydroxy-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-6-beta-D-glucopyranosyl-5,7-dihydroxy-; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-6-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-2-tetrahydropyranyl]-4-chromenone; C01821; NCGC00163566-01; (1S)-1,5-anhydro-1-[2-(3,4-dihydroxyphenyl)-5-hydroxy-7-oxido-4-oxo-4H-chromen-6-yl]-D-glucitol; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-6-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]chromen-4-one; 4261-42-1; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-6-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-methylol-tetrahydropyran-2-yl]chromone; AIDS026707; CHEBI:58333; CHEBI:17965; (1S)-1,5-anhydro-1-[2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-6-yl]-D-glucitol; 6C-hexosyl luteolin; Homoorientin; isoorientin anion; isoorientin ; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-6-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]chromen-4-one; Luteolin 6-C-glucoside | C21H20O11 | 448.377 | c12c(OC(c3c([H])c([H])c(O[H])c(O[H])c3[H])=C([H])C1=O)c([H])c(O[H])c([C@@]4([H])[C@]([H])(O[H])[C@@]([H])(O[H])[C@]([H])(O[H])[C@@]([H])(C([H])([H])O[H])O4)c2O[H] |
| TCMBANKIN046878 | Bilicerdin | bilicerdin | C33H34N4O6 | 582.65 | |
| TCMBANKIN057988 | taurine | N-propyl-4-[5,10,13,14-tetramethyl-3,7,12-tris(oxidanyl)-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]butanamide; A801680; N-propyl-4-(3,7,12-trihydroxy-5,10,13,14-tetramethyl-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl)butanamide | C2H7NO3S | 125.15 g/mol | C(CS(=O)(=O)O)N |
| TCMBANKIN058213 | kaemferol;kampferol;kaempferol;campherol | TNP00039; nchembio.2007.28-comp30; Kaempherol; 5-18-05-00251 (Beilstein Handbook Reference); Prestwick2_001098; CHEBI:28499; Prestwick1_001098; CAS-520-18-3; BRN 0304401; Flavone, 3,4',5,7-tetrahydroxy-; ST030560; MEGxp0_001283; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-hydroxyphenyl)-5,7,4'-Trihydroxyflavonol; C.I. 75640; Swartziol; K0133_SIGMA; kaempferol oxoanion; NCGC00016480-01; 60010_FLUKA; EINECS 208-287-6; Pelargidenon; Nimbecetin; 3,5,7-trihydroxy-2-(4-hydroxyphenyl)-4-chromenone; NSC 407289; 3,4',5,7-Tetrahydroxyflavone; HSCI1_000027; Pelargidenolon 1497; NSC407289; Robigenin; C05903; CPD1F-90; Kampferol; NSC 656277; Prestwick0_001098; 3,5,7-trihydroxy-2-(4-hydroxyphenyl)chromen-4-one; Populnetin; Kampcetin; Prestwick3_001098; AIDS-001404; ZINC00137345; kaempferol ; 5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-3-olate; 3,4′,5,7-Tetrahydroxyflavone; Rhamnolutein; NCGC00016480-02; ACon1_001867; NSC656277; 3,4′,5,7-Tetrahydroxyflavone; BSPBio_001176; SPBio_003058; Oprea1_650954; 5,7,4'-Trihydroxyflavonol; 4H-1-Benzopyran-4-one,3,5,7-trihydroxy-2-(4-hydroxyphenyl)-5,7,4'-Trihydroxyflavonol; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-hydroxyphenyl)- (9CI); Campherol; 520-18-3; 3,5,7-TRIHYDROXY-2-(4-HYDROXYPHENYL)-4H-CHROMEN-4-ONE; S00111; Trifolitin; Kampherol; AI3-36096; 3,5,7-trihydroxy-2-(4-hydroxyphenyl)chromone; Indigo yellow; Pelargidenolon; AIDS001404; nchembio718-comp14; NCGC00091036-01; Flavone, 3,4',5,7-tetrahydroxy- (7CI,8CI); CHEBI:58573; Kaemferol; Kempferol; BPBio1_001294; 3,5,7-Trihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; Rhamnolutin; 3,5,7-triOH-Flavone; KMP; CCRIS 41; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-hydroxyphenyl)- | C15H10O6 | 286.24 g/mol | C1=CC(=CC=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O |
| TCMBANKIN058215 | kaempferol-3-o-beta-d-glucoside | kaempferol-3-O-β-D-glucopyranoside;Kaempferol-3-glucoside;astragalin;Kaempferol-3-o- glucoside;kaempferol 3-glucoside;Kaempferol 3-O-glucoside;kaempferol-3-o-glucoside;5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-3-yl beta-D-glucopyranoside; Kaempferol-3-O-.beta.-D-glucopyranoside; Kaempferol-3-beta-glucopyranoside; 5,7-dihydroxy-2-(4-hydroxyphenyl)-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-chromen-4-one; NCGC00163580-01; 4H-1-Benzopyran-4-one, 3-(beta-D-glucopyranosyloxy)-5,7-dihydroxy-2-(4-hydroxyphenyl)-; Astragaline; 5,7-dihydroxy-2-(4-hydroxyphenyl)-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-chromen-4-one; Kaempferol-3-D-glucoside; 3-(beta-D-glucopyranosyloxy)-5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; MEGxp0_000168; Kaempferol-3-beta-monoglucoside; Kaempferol-3-O-glucoside; 3,4',5,7-Tetrahydroxyflavone-3-glucoside; 480-10-4; ACon1_001224; SCHEMBL23898; 5,7-dihydroxy-2-(4-hydroxyphenyl)-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-methylol-tetrahydropyran-2-yl]oxy-chromone; AIDS-051935; AIDS051935; CHEBI:30200; LMPK12111725; Kaempferol 3-O-beta-D-glucopyranoside; C12249; Astragalin; Kaempferol 3-O-glucoside; Kaempferol 3-glucoside; 5,7-dihydroxy-2-(4-hydroxyphenyl)-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one; Kaempferol 3-O-beta-D-glucoside; 5,7-dihydroxy-2-(4-hydroxyphenyl)-3-[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-2-tetrahydropyranyl]oxy]-4-chromenone;kaempferol-3-β-D-glucopyranoside;Kaempferol-3-O-β-D- glucopyranoside; kaempferol-3-o-beta-d-glucopyranoside;kaempferol-3-O-β-D-glucoside; Kaempferol-3-o-β-D- glucoside; Kaempferol- 3-O-β-D-glucoside | C21H20O11 | 448.38 | C1=CC(=CC=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)OC4C(C(C(C(O4)CO)O)O)O)O |
| TCMBANKIN058363 | n-phenyl-2-naphthylamine | Fenyl-beta -naftylamin; Phenyl-beta-naphtilamine; 4-12-00-03128 (Beilstein Handbook Reference); I14-13875; AC1L1RHP; NCGC00091111-05; W-108255; N-.beta.-Naphthyl-N-phenylamine; MLS002608023; KEQFTVQCIQJIQW-UHFFFAOYSA-N; N-Phenyl-beta -naphthylamine; Antioxidant PBN; N-2-Naphthylaniline; DTXSID4021131; AC-13068; 52907-17-2; CCRIS 853; N-Phenyl-2-naphthylamine; NCGC00091111-01; HSDB 2888; N-beta-Naphthyl-N-phenylamine; KB-55551; N-Phenyl-beta-naphthylamine; CJ-27101; Fenyl-beta-naftylamin; ACMC-209c4p; P.B.N; A807001; Fenyl-beta-naftylamin [Czech]; Stabilizer AR; RL01609; UNII-456KT854AJ; 2-naphthalenamine,n-phenyl-; KS-00000VGP; AC1Q1IST; AN-23110; Jsp002174; DSSTox_RID_75962; 2-naphthylaniline; Naftam 2; NSC 37151; N-Phenyl-2-naphthylamine, 97%; 135-88-6; 2-(N-Phenylamino)naphthalene; N-beta -naphthyl-N-phenylamine; Phenyl-2-naphthylamine; T6903; NCGC00259440-01; Phenyl-beta-naphthylamine; CHEBI:34877; V0380; N-Fenyl-2-aminonaftalen [Czech]; beta-Naphthylphenylamine; SCHEMBL6435930; Oprea1_737712; Neozone; 2-Naphthylphenylamine; 2-Anilinonaphthalene; N-Phenyl-.beta.-amino-naphthalene; STK367409; 2-Phenylaminonaphthalene; Stabilator AR; PBNA; AJ-29138; BIDD:ER0357; EINECS 205-223-9; SCHEMBL38433; NCGC00091111-02; Antioxidant 116; NCGC00256440-01; ac eto pbn; Neozone D; DB-063104; KSC491Q7L; NSC37151; Noclizer D; AKOS001426472; Nocrac D; Neosone D; 2-NAPHTHYLAMINE, N-PHENYL-; Aceto PBN; CTK3J1875; CJ-06100; 2-Naphthalenamine, N-phenyl-; AK-58488; AI3-00068; Fenyl-.beta.-naftylamin; MCULE-5821072787; NCGC00091111-03; InChI=1/C16H13N/c1-2-8-15(9-3-1)17-16-11-10-13-6-4-5-7-14(13)12-16/h1-12,17; Vulkanox PBN; 456KT854AJ; ST50165453; Nonox DN; phenyl-b-naphthylamine; 2-(n-phenylamino)-naphthalene; N-Phenyl-2-naphthalenamine; 84420-28-0; N-Phenyl-.beta.-naphthylamine; neosone d; [2]naphthyl-phenyl-amine; RTR-004823; DSSTox_CID_1131; CHEMBL1543632; beta -naphthylphenylamine; AC1Q4TNM; N-(2-Naphthyl)-N-phenylamine; NSC-37151; BBL000386; ZINC1669780; C14694; .beta.-Naphthylphenylamine; P0198; Neozon D; A-naphthylamine; Nonox DNStabilizer AR; NCGC00091111-04; Stabilator A.R; WLN: L66J CMR; N-Fenyl-2-aminonaftalen; CAS-135-88-6; LS-19; N-Phenylnaphthalen-2-amine; AgeRite Powder; Nilox PBNA; Tox21_201891; TRA0097315; TR-004823; ST24031437; Nonox D; DSSTox_GSID_21131; NCI-C02915; SMR000112180; phenyl-beta -naphthylamine; AK 1 (stabilizer); N-(2-Naphthyl)aniline; ANW-19991; MFCD00004052; Stabilizator AR; BRN 2211188; MolPort-000-514-795; Antioxygene MC; Tox21_302900; Anilinonaphthalene; N-phenyl-N-; Phenyl-.beta.-naphthylamine;135-88-6; Aceto PBN; WLN: L66J CMR; Phenyl-beta-naphtilamine; Phenyl-2-naphthylamine; 4-12-00-03128 (Beilstein Handbook Reference); Phenyl-beta-naphthylamine; AIDS417346; 2-Naphthalenamine, N-phenyl-; AI3-00068; N-Fenyl-2-aminonaftalen [Czech]; N-phenyl-2-naphthalenamine; InChI=1/C16H13N/c1-2-8-15(9-3-1)17-16-11-10-13-6-4-5-7-14(13)12-16/h1-12,17; Vulkanox PBN; AgeRite Powder; beta-Naphthylphenylamine; Nilox PBNA; Oprea1_737712; Neozone; 2-Anilinonaphthalene; 2-Naphthylphenylamine; N-Phenyl-.beta.-amino-naphthalene; Nonox DN; 2-Phenylaminonaphthalene; Antioxidant PBN; N-2-Naphthylaniline; 52907-17-2; CCRIS 853; 84420-28-0; N-Phenyl-2-naphthylamine; N-Phenyl-.beta.-naphthylamine; NCGC00091111-01; ZINC01669780; HSDB 2888; N-Phenyl-beta-naphthylamine; 178055_ALDRICH; EINECS 205-223-9; NCI-C02915; AIDS-417346; NCGC00091111-02; Fenyl-beta-naftylamin [Czech]; AK 1 (stabilizer); Stabilizer AR; Antioxidant 116; N-(2-Naphthyl)aniline; N-phenylnaphthalen-2-amine; Stabilizator AR; 2-Naphthylamine, N-phenyl-; Neozone D; NSC37151; C14694; AK 1; ST5165453; Noclizer D; 2-naphthyl-phenyl-amine; BRN 2211188; NSC 37151; Naftam 2; Nocrac D; .beta.-Naphthylphenylamine; Anilinonaphthalene; Neozon D; Phenyl-.beta.-naphthylamine;Nonox D | C16H13N | 219.28 g/mol | C1=CC=C(C=C1)NC2=CC3=CC=CC=C3C=C2 |
| TCMBANKIN058366 | indigo | [2,2'-BIINDOLYLIDENE]-3,3'-DIOL; (2E)-2-(3-oxo-2-indolinylidene)-3-indolinone; 2-(3-oxo-1H-indol-2-ylidene)-1H-indol-3-one; D&C Blue No. 6; CI Pigment Blue 66; (2E)-2-(3-oxoindolin-2-ylidene)indolin-3-one; Lithosol Deep Blue V; 12626-73-2; FT-0627197; ACon1_002192; NCI-C61392; Indigotin; 12000-74-7; delta(sup 2,2')-Bipseudoindoxyl; Indigo; MCULE-5170690249; 5-24-08-00503 (Beilstein Handbook Reference); ST5308404; (2,2'-Biindoline)-3,3'-dione; Modr Kypova 1 [Czech]; 93660-98-1; 11129-41-2; BRN 0088275; ZINC03861636; NCGC00163355-01; Indigo Blue, Indigotin; 2-(1,3-Dihydro-3-oxo-2H-indol-2-ylidene)-1,2-dihydro-3H-indol-3-one; 68651-46-7; AC1NUZ44; CCRIS 4379; D & C Blue No. 6; HSDB 4372; Indigo (VAN); NSC 8645; AI3-09080; MEGxp0_001924; Indigo (dye); delta2,2'-Bipseudoindoxyl; Indigo,natural; (2E)-2-(3-ketoindolin-2-ylidene)pseudoindoxyl; CI Vat Blue 1; 1H,1'H-[2,2'-BIINDOLYLIDENE]-3,3'-DIONE; C.l. 73000; (delta(sup 2,2')-Biindoline)-3,3'-dione; (delta2,2'(3H,3'H)-Biindole)-3,3'-dione; 2-(1,3-Dihydro-3-oxo-2H-indazol-2-ylidene)-1,2-dihydro-3H-indol-3-one; CTK2F4078; EINECS 207-586-9; (delta2,2'-Biindoline)-3,3'-dione (8CI); 229296_ALDRICH; (2E)-2-(3-oxo-1H-indol-2-ylidene)-1H-indol-3-one; Indigo Blue; (delta2,2'-Biindoline)-3,3'-dione; CI 73000; 2-(1,3-Dihydro-3-oxo-2H-indol-2-ylidene)-1,2-dihydro-3H-indol-3-o- ne;ZINC100513617; D&C Blue 6; (2Z)-2-(3-oxo-1H-indol-2-ylidene)-1H-indol-3-one; D&C Blue No.6; AKOS015900171; [(D)(2,2')-Biindoline]-3,3'-dione; NSC-8645; 2-(3-Hydroxy-2H-indol-2-ylidene)-2H-indol-3-ol; D+C Blue No. 6; C.I Vat blue 1; .DELTA.2,2'-Bipseudoindoxyl; [.DELTA.2,3'H)-Biindole]-3,3'-dione; cis-indigo; NSC8645; [.DELTA.2,3'-dione; ZINC137102896; (2E)-2,2'-biindole-3,3'(1H,1'H)-dione; I14-10736; KB-280044; AC1NS5IU; Indigo Blue; 2-[(2Z)-3-OXO-1H-INDOL-2-YLIDENE]-1H-INDOL-3-ONE; SCHEMBL56085; NCGC00091633-01; D And C Blue Number 6;indigotin | C16H10N2O2 | 262.26 | C1=CC=C2C(=C1)C(=C(N2)C3=NC4=CC=CC=C4C3=O)O |
| TCMBANKIN058367 | indirubin | NSC-105327; KBio2_000450; 2-(2-oxo-1H-indol-3-ylidene)-1H-indol-3-one; 2-(2-oxo-3-indolinylidene)-3-indolinone; Couroupitine B; [.DELTA.2,3'-Biindoline]-2',3-dione; MLS000759416; 479-41-4; 5-24-08-00507 (Beilstein Handbook Reference); KBio3_000839; NSC105327; NSC 105327; (2E)-2-(2-ketoindolin-3-ylidene)pseudoindoxyl; KBioGR_000450; Indigopurpurin; KBioSS_000450; (2E)-2-(2-oxo-1H-indol-3-ylidene)-1H-indol-3-one; indirubin ; (delta2,3'-Biindoline)-2',3-dione (8CI); 2-(2-ketoindolin-3-ylidene)pseudoindoxyl; (delta(sup 2,3')-BIINDOLINE)-2',3-DIONE; Indirubin; (2E)-2-(2-oxoindolin-3-ylidene)indolin-3-one; 2H-Indol-2-one, 3-(1,3-dihydro-3-oxo-2H-indol-2-ylidene)-1,3-dihydro-; SMR000466311; 2H-Indol-2-one, 3-(1,3-dihydro-3-oxo-2H-indol-2-ylidene)-1,3-dihydro- (9CI); BRN 0088279; C.I. 73200; KBio2_005586; (2E)-2-(2-oxo-3-indolinylidene)-3-indolinone; Indigo Red; KBio2_003018; EM-A05-INDIRUBIN; 2-(2-oxoindolin-3-ylidene)indolin-3-one; KBio3_000840; Bio2_000395; Bio2_000875; (2Z)-2-(2-oxo-3-indolinylidene)-3-indolinone; (2Z)-2-(2-oxo-1H-indol-3-ylidene)-1H-indol-3-one; IDI1_002150; BSPBio_001110; NCGC00163356-01; BiomolKI2_000073; NCGC00163356-02; NCGC00163356-03; BiomolKI_000069; (2Z)-2-(2-ketoindolin-3-ylidene)pseudoindoxyl; (2Z)-2-(2-oxoindolin-3-ylidene)indolin-3-one | C16H10N2O2 | 262.26 | C1=CC=C2C(=C1)C(=C(N2)O)C3=NC4=CC=CC=C4C3=O |
| TCMBANKIN058373 | glucobrassicin | 3-Indolylmethylglucosinolate; DNDNWOWHUWNBCK-LDADJPATSA-N; Glucobrassicin; indolylmethyl glucosinolate; 1-S-[(1E)-2-(1H-Indol-3-yl)-N-(sulfooxy)ethanimidoyl]-1-thiohexopyranose #; Glucobrassicine;C05837;glucosinolate | C16H20N2O9S2 | 448.47 | C1=CC=C2C(=C1)C(=CN2)CC(=NOS(=O)(=O)O)SC3C(C(C(C(O3)CO)O)O)O |
| TCMBANKIN058379 | indican | AoEassAssa(1/4)ONI; Indoxyl sulfate potassium salt; AC33706; 487-94-5 (Parent); Sulfuric acid= (1H-indol-3-yl)=potassium ester salt; TRA0056760; SMR000875350; 3-Indoxylsulfuric acid, potassium salt; Potassium indoxyl sulfate; CCG-53133; 2642-37-7; AX8087438; AK-81568; ACM2642377; KS-000018CM; 3-Indoxyl sulfate, potassium salt; SR-01000642319-1; 567HMW942W; MFCD00037931; MolPort-000-141-472; SBB100973; ST24048980; 2355AB; LS-83683; 3-Indoxyl sulfate potassium salt; 3-Indolyl sulphate potassium salt; potassium ion indol-3-yl sulfate; AKOS024306954; Indol-3-ol, potassium sulfate; ANW-58467; DTXSID70181012; 3-hydroxyindol; I14-91729; TC-147212; AKOS016003133; Indol-3-yl sulfate, potassium salt; 1309597-66-7; Indol-3-yl potassium sulfate; Urinary indican; 4CH-021488; SCHEMBL10550536; C8H6KNO4S; indol-3-yl hydroxysulfonate, potassium salt; Indican (urinary); AC1NPD4O; 3-oC>>ussAssaAoEa(1/4)O; 1H-INDOL-3-YL POTASSIUM SULFATE; 1H-Indol-3-ol,3-(hydrogen sulfate), potassium salt (1:1); MLS001361369; 39026A; UNII-567HMW942W; EINECS 220-145-5; Potassium indol-3-yl sulphate; CTK8B7765; FT-0615879; potassium 1H-indol-3-yl sulfate; ST50307657; INDOL-3-OL, HYDROGEN SULFATE (ester), POTASSIUM SALT; CHEMBL1452061; Potassium indol-3-yl sulfate; I-6350; MDAWATNFDJIBBD-UHFFFAOYSA-M;ZINC04097614; (2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-(1H-indol-3-yloxy)oxane-3,4,5-triol; SMP2_000304; 487-60-5; Indican glucoside; (2S,3R,4S,5S,6R)-2-(1H-indol-3-yloxy)-6-methylol-tetrahydropyran-3,4,5-triol; C08481; 1328-73-0; (2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-(1H-indol-3-yloxy)tetrahydropyran-3,4,5-triol;Indican, plant | C14H17NO6 | 295.29g/mol | C1=CC=C2C(=C1)C(=CN2)OC3C(C(C(C(O3)CO)O)O)O |
| TCMBANKIN058380 | ISN | Isatic acid lactam; 5-21-10-00221 (Beilstein Handbook Reference); InChI=1/C8H5NO2/c10-7-5-3-1-2-4-6(5)9-8(7)11/h1-4H,(H,9,10,11; Isotin; SMR000471835; BRN 0383659; 1H-Indole-2,3-dione; MLS001066355; 114618_ALDRICH; 2,3-Dioxoindoline; 2,3-Indolinedione; 91-56-5; AI3-03111; ZINC01532171; Indole-2,3-dione; Isatin; SBB009100; 5815-00-9; Isatinic acid anhydride; 2,3-Diketoindoline; EINECS 202-077-8; o-Aminobenzoylformic anhydride; CHEBI:27539; 58240_FLUKA; AIDS020002; Tribulin; Pseudoisatin; WLN: T56 BMVVJ; AIDS-020002; S00335a; NSC9262; 84788-92-1; Isatine; Indoline-2,3-dione; 2,3-Dioxo-2,3-dihydroindole; C11129; NSC 9262; 2,3-Ketoindoline;isatin;CHEMBL326294; Isotin; Isatin (Compound 1); MFCD00005718; BDBM11022; CAS-91-56-5; 1186480-61-4; MLS001066355; Isatin, for spectrophotometric det. of proline and thiophene, >=99.0%; AC-10666; 2,3-Indolinedione; 2,3-Dioxoindoline; 82X95S7M06; D0SP2O; DSSTox_GSID_38694; Isatin; JXDYKVIHCLTXOP-UHFFFAOYSA-N; SBB009100; HMS2267D18; BB_NC-2184; TRA-0176250; KB-52682; DTXSID3038694; Pseudoisatin; FT-0627212; FT-0728767; KS-00000DIU; Isatin, technical grade; S00335a; Isatine; 2,3-dihydro-1H-indole-2,3-dione; CJ-32724; 2,3-Dioxo-2,3-dihydroindole; 2,3-dihydroindole-2,3-dione; ANW-39708; AM20050218; 5-21-10-00221 (Beilstein Handbook Reference); M-6110; Z57127903; PubChem13609; SMR000471835; AN-24214; AC1Q6GQJ; A843979; D03NEO; 2,3-Indolinedione; Indole-2,3-dione; Isatin, 98% 100g; KSC487A3D; EINECS 202-077-8; CHEBI:27539; NSC-9262; Tribulin; 3-Hydroxy-2H-indol-2-one; CS-W020128; 3-Indolinedione; AK-29599; 3-hydroxy-2-indolone; WLN: T56 BMVVJ; Tox21_202876; SC-18090; FC0204; AKOS000119125; TR-028840; 84788-92-1; Indoline-2,3-dione; C11129; ST50213409; Isatic acid lactam; ZINC2047514; InChI=1/C8H5NO2/c10-7-5-3-1-2-4-6(5)9-8(7)11/h1-4H,(H,9,10,11; UNII-82X95S7M06; 2,3-Dihydro-indole-2,3-dione; I-7801; BRN 0383659; 1H-Indole-2,3-dione; 1H-benzo[d]azoline-2,3-dione; BBL002302; MolPort-000-871-222; ACMC-209rce; RP17346; 91-56-5; AI3-03111; DSSTox_RID_79385; Isatin, p.a.; 5815-00-9; LS21014; I0080; o-Aminobenzoylformic anhydride; CTK3I7031; BR-29599; I-7800; Indole-2,3-dione; 2,3-Indolinedione; 1H-Indole-2,3-dione; F9995-1662; NCGC00260422-01; AC1L1NWG; s4717; BG00600517; S10-0023; NSC9262; 2,3-Ketoindoline; DB02095; AB1002676; AJ-33433; INDOLE-2,3-DIONE; DSSTox_CID_18694; EC 202-077-8; LS-83004; hydroxy-3-indolone; NCGC00246983-01; 2,3-dihydro-1H-indol-2,3-dione; CJ-32725; MCULE-2273580482; Isatinic acid anhydride; EBD271; 2,3-Diketoindoline; 2H-indole-2,3-dione; RTR-028840; DB-061345; ST2413137; BC679623; AZ0001-0080; SCHEMBL34016; BG01498796; KB-236288; AS-10908; STK387523; NSC 9262 | C8H5NO2 | 147.13 | C1=CC=C2C(=C1)C(=O)C(=O)N2 |
| TCMBANKIN058390 | tryptanthrine | AC1L2K2A; SMR000386951; Indolo(2,1-b)quinazoline-6,12-dione; NSC-349447; MLS001049121; SR-01000521538-1; Indolo(2,1-b)quinazoline-6,12-dione (8CI)(9CI); FT-0733127; Couroupitine a; Tryptanthrin; KS-00000C3R; C-45803; Tryptantherin; NCGC00160337-02; GNF-PF-2691; NSC349447; AK-57813; TCMDC-125859; Tryptanthrin, >=98% (HPLC); NCI60_003113; ZB000930; DS-15687; KB-254423; SR-01000521538-4; ST047334; CHEMBL306946; CJ-00188; Indolo[2,1-b]quinazoline-6,12-dione; 5941AA; NCGC00160337-01!TRYPTANTHRINE; 13220-57-0; SCHEMBL2426211; STK078931; NCGC00160337-01; AKOS000671350; Bio-0284; HMS2271H05; Indolo[2,1-b]quizoline-6,12-dione; SY017117; 11-hydrobenzo[d]quinazolino[3,2-a]azolidine-6,12-dione; ANW-68868; ZINC33299; MCULE-7521697515; CTK0H6551; TRA0036916; SR-01000521538; J-006143; AX8156048; BDBM50240612; AC1Q1HJD; TC-157613; K-4146; Tryptanthrine; D0I9AT; MFCD00012073; GTPL8224; CCG-208326; NSC 349447; AJ-08570; CHEBI:9768; DTXSID90157431; VQQVWGVXDIPORV-UHFFFAOYSA-N; C10742; Oprea1_754264; Indolo[2,12-dione; MolPort-002-516-459; AC1L2K2A; indolo[2,1-b]quinazoline-6,12-quinone; SMR000386951; Indolo(2,1-b)quinazoline-6,12-dione; NSC-349447; MLS001049121; SR-01000521538-1; Indolo(2,1-b)quinazoline-6,12-dione (8CI)(9CI); FT-0733127; Couroupitine a; Tryptanthrin; KS-00000C3R; C-45803; Tryptantherin; NCGC00160337-02; GNF-PF-2691; NSC349447; AK-57813; TCMDC-125859; Tryptanthrin, >=98% (HPLC); NCI60_003113; ZB000930; DS-15687; KB-254423; SR-01000521538-4; ST047334; CHEMBL306946; CJ-00188; tryptanthrin ; Indolo[2,1-b]quinazoline-6,12-dione; 5941AA; NCGC00160337-01!TRYPTANTHRINE; 13220-57-0; SCHEMBL2426211; STK078931; NCGC00160337-01; AKOS000671350; Bio-0284; indolo[2,1- b]quinazoline alkaloid; HMS2271H05; indolo-[2,1-b]-quinazoline-6,12-dione; Indolo[2,1-b]quizoline-6,12-dione; SY017117; 11-hydrobenzo[d]quinazolino[3,2-a]azolidine-6,12-dione; ANW-68868; ZINC33299; MCULE-7521697515; CTK0H6551; TRA0036916; AIDS017287; SR-01000521538; J-006143; ZINC00033299; AX8156048; BDBM50240612; 6,12-dihydro-6, 12-dioxoindolo-(2,1-b)-quinazoline; AC1Q1HJD; TC-157613; K-4146; Tryptanthrine; D0I9AT; MFCD00012073; GTPL8224; CCG-208326; NSC 349447; AJ-08570; AIDS-017287; CHEBI:9768; DTXSID90157431; VQQVWGVXDIPORV-UHFFFAOYSA-N; C10742; Oprea1_754264; Indolo[2,12-dione; MolPort-002-516-459; tryptanthrin | C15H8N2O2 | 248.24 g/mol | C1=CC=C2C(=C1)C(=O)N3C4=CC=CC=C4C(=O)C3=N2 |
| TCMBANKIN058450 | ADO | nchembio.2007.56-comp13; CHEBI:16335; Bio1_000437; 9-beta-D-Ribofuranosyl-9H-purin-6-amine; AIDS-001224; 9beta-D-Ribofuranosyladenine; BSPBio_001796; beta-Adenosine; (2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-methylol-tetrahydrofuran-3,4-diol; beta-D-Ribofuranoside, adenine-9; D00045; 46969-16-8; SDCCGMLS-0003108.P003; 4-Aminopyrazolo[3,4-d]pyrimidine ribonucleoside; (2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; 6-Amino-9-.beta.-ribofuranosyl-9H-purine; NSC 7652; Bio1_001415; Adenosine (JAN/USP); Spectrum2_001257; Spectrum3_000288; Adenosine, homopolymer; ADN; Caswell No. 010B; Adenocard; C00212; SR 96225; Adenocard (TN); EINECS 200-389-9; KBio3_001296; 9H-Purin-6-amine, 9beta-D-ribofuranosyl-; Polyadenosine; beta-D-Ribofuranose, 1-(6-amino-9H-purin-9-yl)-1-deoxy-; (2R,3R,4S,5R)-2-(6-amino-9-purinyl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol; MLS000069638; AI3-52413; 9-beta-D-Ribofuranosidoadenine; A9251_SIGMA; Adenoscan (TN); Bio1_000926; ZINC02169830; CCRIS 2557; NCGC00023673-05; Ade-Rib; nchembio706-5; 30143-02-3; 6-Amino-9-beta-D-ribofuranosyl-9H-purine; Adenosin [German]; NSC 627048; SMR000058216; 9-beta-D-Ribofuranosyladenine; SPBio_001194; beta-D-Adenosine; Adenosine [USAN:BAN]; Polyriboadenosine; (2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol; AIDS001224; 6-Amino-9beta-D-ribofuranosyl-9H-purine; ST009496; Adenoscan; A4036_SIGMA; SPECTRUM1500107; 46946-45-6;SCHEMBL170902; adenosine ; AKOS015960342; AC-5504; BC200893; Adenosine;adenosine;adeninenucleoside | C10H13N5O4 | 267.24 g/mol | C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N |
| TCMBANKIN058798 | Glycyrol | MLS000697623; C16968; MolPort-039-339-022; AIDS095929; Neoglycyrol; 4CN-3163; CHEMBL132695; AKOS032949068; ZINC13130921; CHEBI:80832; 3,9-dihydroxy-1-methoxy-2-(3-methylbut-2-enyl)-[1]benzoxolo[3,2-c]chromen-6-one; 3,9-dihydroxy-1-methoxy-2-(3-methylbut-2-enyl)-[1]benzofuro[3,2-c]chromen-6-one; AIDS-095929; HMS2270J05; 3,9-Dihydroxy-1-methoxy-2-(3-methyl-but-2-enyl)-benzofuro[3,2-c][1]benzopyran-6-one; 23013-84-5; DTXSID00177569; 3,9-dihydroxy-1-methoxy-2-(3-methylbut-2-enyl)-6-benzofurano[3,2-c]chromenone; SCHEMBL758197; AC1NSZ1D; 3,9-dihydroxy-1-methoxy-2-(3-methylbut-2-enyl)benzofuro[3,2-c]chromen-6-one; 3,9-dihydroxy-1-methoxy-2-(3-methylbut-2-enyl)benzofurano[3,2-c]chromen-6-one; SMR000470955; 3,9-dihydroxy-1-methoxy-2-(3-methylbut-2-en-1-yl)-6H-[1]benzofuro[3,2-c][1]benzopyran-6-one; 3,9-Dihydroxy-1-methoxy-2-prenylcoumestan; 6H-Benzofuro(3,2-c)(1)benzopyran-6-one, 3,9-dihydroxy-1-methoxy-2-(3-methyl-2-butenyl)-; glycyrol;neoglycyrol | C21H18O6 | 366.4 g/mol | CC(=CCC1=C(C2=C(C=C1O)OC(=O)C3=C2OC4=C3C=CC(=C4)O)OC)C |
| TCMBANKIN059099 | Marmesine;nodakenetin | (2R)-2-(1-hydroxy-1-methyl-ethyl)-2,3-dihydrofuro[3,2-g]chromen-7-one; 7H-FURO(3,2-g)(1)BENZOPYRAN-7-ONE, 2,3-DIHYDRO-2-(1-HYDROXY-1-METHYLETHYL)-, (S); C09278; (2R)-2-(2-hydroxypropan-2-yl)-2,3-dihydrofuro[3,2-g]chromen-7-one; STOCK1N-61085; AIDS071123; ZINC00051923; 495-32-9; marmesine; NSC 340840; AIDS-071123; 7H-Furo(3,2-g)(1)benzopyran-7-one, 2,3-dihydro-2-(1-hydroxy-1-methylethyl)-, (S)-(+)-; CCRIS 5728; 1/C14H14O4/c1-14(2,16)12-6-9-5-8-3-4-13(15)18-10(8)7-11(9)17-12/h3-5,7,12,16H,6H2,1-2H; (2R)-2-(1-hydroxy-1-methylethyl)-2,3-dihydrofuro[3,2-g]chromen-7-one; 7H-furo[3,2-g][1]benzopyran-7-one, 2,3-dihydro-2-(1-hydroxy-1-methylethyl)-; (S)-Marmesin; 7H-Furo(3,2-g)(1)benzopyran-7-one, 2,3-dihydro-2-(1-hydroxy-1-methylethyl)-, (R)-; (-)-Marmesin; Nodakenitin; 2-(1-hydroxy-1-methylethyl)-2,3-dihydro-7H-furo[3,2-g]chromen-7-one; 7H-Furo[3,2g][1]-benzopyran-7-one, (-2,3-dihydro-2-(1-hydroxy-1-hydroxymethylethyl)-, (R); (R)-2-(1-Hydroxy-1-methylethyl)-2,3-dihydro-7H-furo(3,2-g)(1)benzopyran-7-one; Nodakenetin;ST4038313; FWYSBEAFFPBAQU-UHFFFAOYSA-N; ( inverted exclamation markA)-Marmesin; MCULE-3188434807; BAS 00015462; 2-(1-hydroxy-1-methyl-ethyl)-2,3-dihydrofuro[3,2-g]chromen-7-one; 2-(1-Hydroxy-1-methyl-ethyl)-2,3-dihydro-furo[3,2-g]chromen-7-one; 2-(2-hydroxypropan-2-yl)-2,3-dihydrofuro[3,2-g]chromen-7-one; 2-(1-Hydroxy-1-methylethyl)-2,3-dihydro-7H-furo[3,2-g]chromen-7-one; Marmesin; 2-(1-Hydroxy-1-methylethyl)-2,3-dihydrofuro[3,2-g]chromen-7-one; SCHEMBL546574; 2-(2-hydroxypropan-2-yl)-2,3-dihydro-7H-furo[3,2-g]chromen-7-one; Oprea1_172287; AC1LCPS5; AKOS022062475; HMS1672K17; MolPort-001-913-428; 2'-(1''-Hydroxy-1''-methylethyl)-psoralen; STK396315; A1784/0075601; 2-(1-Hydroxy-1-methylethyl)-2,3-dihydro-7H-furo[3,2-g]chromen-7-one #; 2,3-dihydro-2-(1-hydroxy-1-methylethyl)-7h-furo[3,2-g][1]benzopyran-7-one; 13710-70-8; InChI=1/C14H14O4/c1-14(2,16)12-6-9-5-8-3-4-13(15)18-10(8)7-11(9)17-12/h3-5,7,12,16H,6H2,1-2H; (S)-Marmesin; CHEBI:49080; Oprea1_468691; 7-(2-hydroxypropan-2-yl)-2H,6H,7H-furo[3,2-g]chromen-2-one; Q-100147; ST097606; AKOS000546749; 2-(1-hydroxy-isopropyl)-2,3-dihydrofurano[3,2-g]chromen-7-one | C14H14O4 | 246.26 | CC(C)(C1CC2=C(O1)C=C3C(=C2)C=CC(=O)O3)O |
| TCMBANKIN059147 | ergosterin | ergosterol;24-Methylcholesta-5,7,22-trien-3beta-ol; 24alpha-Methyl-22E-dehydrocholestero; (3beta,22E)-Ergosta-5,7,22-trien-3-ol; (7S,9AR,11AR)-1-[(2R,3E,5R)-5,6-DIMETHYLHEPT-3-EN-2-YL]-9A,11A-DIMETHYL-1H,2H,3H,3AH,6H,7H,8H,9H,9BH,10H,11H-CYCLOPENTA[A]PHENANTHREN-7-OL; 45480_FLUKA; (24R)-Ergosta-5,7,22-trien-3b-ol; MEGxm0_000450; Ergosterin; 24R-Methylcholesta-5,7,22E-trien-3b-ol; 57-87-4; Ergosterol; ergosta-5,7,22E-trien-3beta-ol; (3beta)-Ergosta-5,7,22-trien-3-ol; C01694; 5,7,22-Ergostatrien-3beta-ol; AIDS064232; E6510_SIGMA; Provitamin D2; (22E)-Ergosta-5,7,22-trien-3.beta.-ol; A831651; ergosta-5,7,22-trienol; ergosta-5,7,22-trien-3 beta-ol; 24R-Methylcholesta-5,7,22E-trien-3beta-ol; ACon0_000429; ERG; ST073383; (3S,10R,13R)-17-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-10,13-dimethyl-2,3,4,9,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol; 24-Methylcholesta-5,7,22-trien-3b-ol; ACon1_000637; (3beta,2E)-Ergosta-5,7,22-trien-3-ol; Provitamine D2; AIDS-064232; 24a-Methyl-22E-dehydrocholesterol; ergosta-5,7,22-trien-3-ol; 47130U_SUPELCO; LMST01030093; (22E)-ergosta-5,7,22-trien-3beta-ol; ZINC04084618; (3S,9S,10R,13R,14R,17R)-17-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-10,13-dimethyl-2,3,4,9,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol; 3beta-Hydroxy-5,7,22-ergostatriene; CHEBI:16933; (3S,9S,10R,13R,14R,17R)-10,13-dimethyl-17-[(E,1R,4R)-1,4,5-trimethylhex-2-enyl]-2,3,4,9,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol; (22E,24S)-24-methylcholesta-5,7,22-trien-3beta-ol | C28H44O | 396.6 g/mol | CC(C)C(C)C=CC(C)C1CCC2C1(CCC3C2=CC=C4C3(CCC(C4)O)C)C |
| TCMBANKIN059249 | CLR | 5-Cholesten-3b-ol; Hydrocerin; 5:6-Cholesten-3beta-ol; 209124-38-9; Lidinite; 5:6-Cholesten-3.beta.-ol; Tegolan (VAN); C1231_SIGMA; 3-beta-Hydroxycholest-5-ene; Delta5-Cholesten-3beta-ol; C3292_SIGMA; (3H)-Cholesterol; 20808_RIEDEL; S5442_SIGMA; Cholest-5-en-3-ol, (3-.beta.)-; Super hartolan; Cholesterol (JP15/NF); AIDS338945; 5:6-Cholesten-3-ol; nchembio782-comp1; 3beta-Hydroxy-5-cholestene; delta(sup 5)-Cholesten-3-beta-ol; Dusoline; CHOLESTEROL; D00040; C00187; Provitamin D; Wool alcohols B. P.; Cholest-5-en-3-ol, (3beta)-; Synthetic cholesterol; Dythol; CMC_13392; HSDB 7106; 3beta-Hydroxycholest-5-ene; Cordulan; 5,6-Cholesten-3.beta.-ol; Cholest-5-en-3.beta.-ol; 57-88-5; Kathro; Dusoran; (3beta)-cholest-5-en-3-ol; WLN: L E5 B666 LUTJ A1 E1 FY1&3Y1&1 OQ; 3.beta.-Hydroxycholest-5-ene; 26740_FLUKA; Cholesterol base H; Cholest-5-en-3-ol (3beta)-, labeled with tritium; NCGC00159351-02; 80356-14-5; Cholest-5-en-3-ol, (3.beta.)-; Cholestrin; 5-Cholesten-3beta-ol; ZINC03875383; 218965-24-3; 26732_FLUKA; Cholesterin; C8667_SIGMA; 22243-67-0; Lidinit; Phospholipon & Cholesterol; CHEBI:16113; SyntheChol NS0 Supplement; NSC 8798; nchembio.77-comp1; AI3-03112; Lanol; Cholestrol; AIDS080405; Cholest-5-en-3-ol (3beta)-; 5-Cholesten-3.beta.-ol; SyntheChol; NSC8798; Cholesterol solution; Cholesterol [USAN:JAN]; Nimco cholesterol base H; C8503_SIGMA; BB_NC-0135; SMP1_000069; C3137_SIGMA; Cholesterine; 47127U_SUPELCO; Cholest-5-en-3-beta-ol; Nimco cholesterol base No. 712; AIDS-338945; Cholesteryl alcohol; C3045_SIGMA; 14606_FLUKA; Soya phospholipon & Cholesterol (2:1 molar ratio); AIDS-080405; LMST01010001; CCRIS 2834; (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; Cholest-5-en-3beta-ol; Cholesterol (TN); EINECS 200-353-2; Tegolan;cholesterol;8(14)-dehydrocholesterol; 177962-82-2; SCHEMBL5347436; cholesta-5,8(14)-dien-3beta-ol; DJNCIOAUQVURTQ-RQZUOROGSA-N | C27H46O | 386.65 | CC(C)CCCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C |
| TCMBANKIN059333 | glycocholicacid | glycocholic acid | C26H43NO6 | 465.6 g/mol | CC(CCC(=O)NCC(=O)O)C1CCC2C1(C(CC3C2C(CC4C3(CCC(C4)O)C)O)O)C |
| TCMBANKIN059337 | CHD;cholalic acid;cholicacid | 5beta-Cholanic acid, 3alpha,7alpha,12alpha-trihydroxy- (7CI); cholic acid; 3alpha,7alpha,12alpha-Trihydroxycholanic acid; 81-25-4 (FREE ACID); CHOLATE; 3alpha,7alpha,12alpha-Trihydroxy-5beta-cholanic acid; 3alpha,7alpha,12alpha-trihydroxy-5beta-cholan-24-oic acid; 3alpha,7alpha,12alpha-Trihydroxy-5beta-cholanoic acid; (3alpha,5beta,7alpha,12alpha)-3,7,12-trihydroxycholan-24-oic acid; 3alpha,7alpha,12alpha-Trihydroxy-beta-cholanic acid; (4R)-4-[(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid; Colalin; C9377_SIGMA; SMR000112165; 3.alpha.,7.alpha.,12.alpha.-Trihydroxy-5.beta.-cholanic acid; AIDS017669; 5.beta.-Cholan-24-oic acid, 3.alpha.,7.alpha.,12.alpha.-trihydroxy-; MLS001066422; Cholan-24-oic acid, 3,7,12-trihydroxy-, (3alpha,5beta,7alpha,12alpha)- (9CI); AIDS-017669; Cholic acid (8CI); Cholalic acid; Cholan-24-oic acid, 3,7,12-trihydroxy-, (3-alpha,5-beta,7-alpha,12-alpha)-; Cholsaeure; C1129_SIGMA; ST024722; Spectrum5_002005; 5beta-Cholanic acid-3alpha,7alpha,12alpha-triol 5beta-Cholic acid; Cholalin; 17beta-[1-Methyl-3-carboxypropyl]etiocholane-3alpha,7alpha,12alpha-triol; 73163-53-8 (NA SALT); NSC-6135; 81-25-4; 3-&alpha,7-&alpha,12-&alpha-trihydroxy-5-&beta-cholanate; (3.alpha.,5.beta.,7.alpha.,12.alpha.)-3,7,12-Trihydroxycholan-24-oic acid sodium salt; (4R)-4-[(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]valeric acid; NSC6135; CHEBI:16359; C00695; LMST04010001;cholic acid;cholic acid | C24H40O5 | 408.57;408.6 g/mol | CC(CCC(=O)O)C1CCC2C1(C(CC3C2C(CC4C3(CCC(C4)O)C)O)O)C |
| TCMBANKIN060691 | poriferast-5-en-3beta-ol;22,23-dihydrostigmasterol;gamma-sitosterol;clionasterol;beta-dihydrofucosterol | C29H50O | 414.71 g/mol | CCC(CCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C)C(C)C | |
| TCMBANKIN061149 | 1-dotriacontanol | C32H66O | 466.9 g/mol | CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO | |
| TCMBANKIN061849 | 1-methoxy-4-(2-propenyl)-benzene | 4-Allylanisole;estragole;esdragol;Terragon;methylchavicol;CCRIS 1317; MolPort-000-156-967; MFCD00008653; Estragol (methylchavicol); DSSTox_CID_575; Anisole, p-allyl-; Esdragol; 1-allyl-4-methoxy-benzene; DTXSID0020575; 4-allylanisol; Methyl chavicole (estragole); p-Methoxyallylbenzene; Benzene, 1-methoxy-4-(2-propen-1-yl)-; NCGC00091434-01; chavicyl methylether; CTK7A3557; Methyl chavicole; UNII-9NIW07V3ET; Estragol; SR-01000838348; 4-06-00-03817 (Beilstein Handbook Reference); Ether, p-allylphenyl methyl; NSC 404113; Tarragon; 140-67-0; DSSTox_RID_75667; O080; Chavicol methyl ether; Benzene, 1-methoxy, 4-prop-2-enyl; AK109291; FEMA No. 2411; p-Allylphenyl methyl ether; p-allylanisole, 4-allyl-1-methoxybenzene, methyl chavicol; Chavicol, O-methyl-; NSC-404113; CHEMBL470671; CCG-214642; 4-Allylanisole, analytical standard; FEMA 2411; 1-METHOXY-4-(2-PROPENYL)BENZENE; FEMA Number 2411; EPA Pesticide Chemical Code 062150; 4-Allylmethoxybenzene; Benzene, 1-methoxy-4-(2-propenyl)-; HMS2268E24; SMR000112379; p-Allylanisole; SPECTRUM1505117; 1-methoxy-4-(prop-2-en-1-yl)benzene; Chavicyl methyl ether; chavicol methylether; C10452; NCI-C60946; Allylphenyl methyl ether, p-; estragon;p-allylanisole; EINECS 205-427-8; AI3-16052; Esteragol; ZINC967635; 4-Allylanisole, purum, >=97.0% (GC); CHEBI:4867; 1407-27-8; Estragole (natural); NCGC00259936-01; MLS001065575; 1-methoxy-4-prop-2-enylbenzene; Methyl chavicol; AC1Q4FE9; 1-Methoxy-4-(2-propen-1-yl)-Benzene; Methylchavicol; Chavicol, methyl-; p-Allyl-Anisole; ACMC-1BW75; KB-36193; 3-(p-Methoxyphenyl)propene; 1-methoxy-4-(2-propenyl)-benzene; InChI=1/C10H12O/c1-3-4-9-5-7-10(11-2)8-6-9/h3,5-8H,1,4H2,2H; AKOS000121300; p-Allylmethoxybenzene; Methyl-Chavicol; AC1L1RR7; Tox21_302930; 3-(4-Methoxyphenyl)-1-propene; ST50824126; BRN 1099454; Isoanthethole; LS-821; Esdragon; ZFMSMUAANRJZFM-UHFFFAOYSA-N; I01-10181; Estragole, analytical standard; 9NIW07V3ET; O-Methyl-Chavicol; Terragon; 4-Allyl-1-methoxybenzene; BENZENE,1-ALLYL,4-METHOXY METHYLCHAVICOL; HSDB 5412; 4-Allylanisole, 98%; Chavicyl methyl ether; AN-17349; 1-Methoxy-4-(2-propenyl)benzene, 9CI; A0702; 4-Allylanisole; para-allylanisole; AC1Q4CFH; SCHEMBL57204; WLN: 1U2R DO1; SR-01000838348-2; FT-0617414; J-007415; NCGC00091434-02; TC-109325; CAS-140-67-0; isoanethole, 4-Allylanisole; ANW-20580; 4-Methoxyallylbenzene; Tox21_202387; Estragole; NSC404113; Esdragole; 77525-18-9; AJ-24538; DSSTox_GSID_20575; NCGC00091434-03; Para-allylanisole (estragole); ZB015470; BENZENE,1-ALLYL,4-METHOXY METHYLCHAVICOL; 1-Allyl-4-methoxybenzene; NCGC00256481-01; 4-Allylanisole, >=98%, FCC; 1-Methoxy-4-(2-propen-1-yl)benzene; Isoanethole;34098_RIEDEL; 3-(p-Methoxyphenyl)propene; InChI=1/C10H12O/c1-3-4-9-5-7-10(11-2)8-6-9/h3,5-8H,1,4H2,2H; 1-METHOXY-4-(2-PROPENYL)BENZENE; Anisole, p-allyl-; EPA Pesticide Chemical Code 062150; 1-allyl-4-methoxy-benzene; Esdragol; FEMA Number 2411; p-Allylmethoxybenzene; NCGC00091434-02; 4-Allylmethoxybenzene; Benzene, 1-methoxy-4-(2-propenyl)-; p-Methoxyallylbenzene; 4-Methoxyallylbenzene; BRN 1099454; WLN: 1U2R DO1; SPECTRUM1505117; p-Allylanisole; LS-821; Esdragon; NCGC00091434-01; Estragol; Chavicyl methyl ether; C10452; Estragole; 4-06-00-03817 (Beilstein Handbook Reference); NSC404113; Esdragole; NCI-C60946; NSC 404113; 77525-18-9; 4-Allyl-1-methoxybenzene; Tarragon; 140-67-0; Allylphenyl methyl ether, p-; HSDB 5412; EINECS 205-427-8; ZINC00967635; AI3-16052; Isoanethole; 1-methoxy-4-prop-2-enyl-benzene; A29208_ALDRICH; 05820_FLUKA; Chavicol methyl ether; 05818_FLUKA; BENZENE,1-ALLYL,4-METHOXY METHYLCHAVICOL; 1407-27-8; W241105_ALDRICH; Estragole (natural); 1-Allyl-4-methoxybenzene; FEMA No. 2411; 4-Allylanisole; 1-Methoxy-4-(2-propen-1-yl)benzene; Chavicol, O-methyl-; 1-methoxy-4-prop-2-enylbenzene; Methyl chavicol; Methylchavicol | C10H12O | 148.2 g/mol | COC1=CC=C(C=C1)CC=C |
| TCMBANKIN061934 | neoglucobrassicin | Neoglucobrassicin; 1-(Oxylatosulfonyloxyimino)-2-(1-methoxy 1H-indole-3-yl)ethyl 1-thio-beta-D-glucopyranoside; CHEBI:64965; neoglucobrassicin(1-); 1-S-[2-(1-methoxy-1H-indol-3-yl)-N-(sulfonatooxy)ethanimidoyl]-1-thio-beta-D-glucopyranose; neoglucobrassicin anion; beta-D-Glucopyranose, 1-thio-, 1-(1-methoxy-N-(sulfooxy)-1H-indole-3-ethanimidate); [[2-(1-methoxyindol-3-yl)-1-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]sulfanyl-ethylidene]amino] hydrogen sulfate; [[2-(1-methoxyindol-3-yl)-1-[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-methylol-tetrahydropyran-2-yl]thio]ethylidene]amino] hydrogen sulfate; [[2-(1-methoxyindol-3-yl)-1-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]sulfanyl-ethylidene]amino] hydrogen sulfate; [[2-(1-methoxy-3-indolyl)-1-[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-2-tetrahydropyranyl]thio]ethylidene]amino] hydrogen sulfate; [[2-(1-methoxyindol-3-yl)-1-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]sulfanylethylidene]amino] hydrogen sulfate | C17H22N2O10S2 | 478.5 g/mol | CON1C=C(C2=CC=CC=C21)CC(=NOS(=O)(=O)O)SC3C(C(C(C(O3)CO)O)O)O |
植物对应的疾病
| 疾病ID | 病名 | 疾病类型 | MeSH | 参考文献 |
|---|
植物对应的靶点
| 靶点ID | 基因名 | 基因别名 | 描述 | 染色体位置 | Map_Location | 基因类型 |
|---|
滇ICP备16009434号-1 |
Dai SX Lab